PAROXETINE HYDROCHLORIDE Drug Patent Profile

When do Paroxetine Hydrochloride patents expire, and what generic alternatives are available?

Paroxetine Hydrochloride is a drug marketed by Annora Pharma, Apotex Inc, Novitium Pharma, Alembic, Aurobindo Pharma Usa, Cadila Pharms Ltd, Cspc Ouyi, Epic Pharma Llc, Lannett Co Inc, Lupin Ltd, Prinston Inc, Sciecure Pharma Inc, Apotex, Aurobindo Pharma, Chartwell Rx, Jubilant Generics, Mylan, Oxford Pharms, Pharmobedient, Roxane, Sun Pharm Inds Inc, Teva Pharms, Upsher Smith Labs, Yiling, and Zydus Pharms Usa. and is included in twenty-six NDAs.

The generic ingredient in PAROXETINE HYDROCHLORIDE is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Paroxetine Hydrochloride

A generic version of PAROXETINE HYDROCHLORIDE was approved as paroxetine hydrochloride by APOTEX on July 30^th, 2003.

Summary for PAROXETINE HYDROCHLORIDE

US Patents:	0
Applicants:	25
NDAs:	26
Finished Product Suppliers / Packagers:	41
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	271
Patent Applications:	1,114
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PAROXETINE HYDROCHLORIDE
What excipients (inactive ingredients) are in PAROXETINE HYDROCHLORIDE?	PAROXETINE HYDROCHLORIDE excipients list
DailyMed Link:	PAROXETINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for PAROXETINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medipol University	NA
BioNTech SE	PHASE1
South Valley University	NA

See all PAROXETINE HYDROCHLORIDE clinical trials

Pharmacology for PAROXETINE HYDROCHLORIDE

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for PAROXETINE HYDROCHLORIDE

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for PAROXETINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PAXIL CR	Extended-release Tablets	paroxetine hydrochloride	37.5 mg	020936	1	2009-05-19
PAXIL CR	Extended-release Tablets	paroxetine hydrochloride	25 mg	020936	1	2005-09-09

US Patents and Regulatory Information for PAROXETINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	075566-003	Mar 8, 2004		DISCN	No	No
Chartwell Rx	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	076618-004	Aug 15, 2005	AB	RX	No	No
Apotex	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	075356-003	Jul 30, 2003	AB	RX	No	No
Mylan	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	078902-004	Mar 13, 2008	AB	RX	No	No

Market Dynamics and Financial Trajectory for Paroxetine Hydrochloride

Last updated: February 20, 2026

What is the Current Market Size and Growth Potential?

Paroxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI) approved for depression, anxiety disorders, OCD, PTSD, and other mental health conditions. The global antidepressant market was valued at approximately USD 14.9 billion in 2022, with SSRIs accounting for a major share (approximately 70%). Paroxetine's market segment is significant within this, especially in North America, Europe, and parts of Asia-Pacific (IBISWorld, 2023).

Forecasts indicate a compound annual growth rate (CAGR) of 3-4% over the next five years for the broader antidepressant sector. Paroxetine specifically is likely to sustain steady sales due to longstanding efficacy but faces competition from newer agents with improved side effect profiles.

How Does Patent Status Affect Market Exclusivity?

The original patent for paroxetine hydrochloride expired in 2001. Since then, generic formulations dominate the market, reducing manufacturer revenue from brand-name versions. As of 2023, only limited patents or exclusivities remain in select jurisdictions:

• Patents related to formulations and methods may still provide some market control in specific regions.
• Data exclusivity periods (typically 5-8 years post-approval) have expired in most markets, enabling generics to enter.

Generic entry in the early 2000s caused a sharp decline in precio, with wholesale prices dropping by an estimated 75%. The loss of patent protection means the original brand no longer captures significant market share.

What Are the Key Market Players and Competitive Dynamics?

Major current players include:

• Teva Pharmaceuticals: Produces the most widely prescribed generic paroxetine.
• Mylan/Biocon & Sandoz: Also offer competing generics.
• Pfizer: Marketed Paxil before patent expiry; now primarily involved in generic versions.

The generic competition has led to price erosion, with multiple suppliers offering bioequivalent formulations at lower prices.

Market penetration factors:

• Prescriber familiarity with paroxetine.
• Clinician preference based on side effect profiles.
• Insurance formularies favoring low-cost generics.

The emergence of newer antidepressants like vortioxetine or vilazodone has slightly dampened growth prospects, but paroxetine remains relevant where cost is a primary concern.

What Are the Regulatory and Policy Challenges?

Regulatory frameworks influence market access:

• FDA and EMA approvals are relatively stable, with no recent major restrictions on generic sales.
• Post-marketing safety alerts (e.g., concerns about withdrawal or side effects) can influence prescribing patterns.
• Pricing policies in countries like the UK’s NHS or formulary controls in the US impact sales volume and pricing strategies for generics.

Generics face few barriers in most jurisdictions, although some markets enforce strict bioequivalence standards.

What Is the Financial Outlook for Manufacturers?

Given the widespread generic presence, revenue from paroxetine deteriorated significantly post-patent expiry:

Metric	Data	Context
Revenue decline	Estimated 75-85% (2001–2005)	After patent expiration
Current annual sales	Estimated USD 200-300 million	In global generics markets
Market share (by volume)	Over 50% of generic antidepressants	In major markets

Profit margins are compressed due to commoditization:

• Gross margins for generic formulations typically hover around 10-15%.
• R&D investments are minimal, mainly related to manufacturing efficiency or formulation improvements.

Newer formulations or indications (e.g., paroxetine CR or combination products) do not significantly impact core sales, as generic competition dominates.

What Are Future Opportunities and Risks?

Opportunities:

• Development of specialized formulations (e.g., extended-release or fixed-dose combinations).
• Geographic expansion into emerging markets with growing mental health awareness.
• Potential licensing agreements for new indications or bioequivalent variations.

Risks:

• Market saturation due to high generic availability.
• Regulatory shifts limiting marketing practices.
• Competition from newer, patent-protected antidepressants.

Key Market Drivers and Challenges

Drivers	Challenges
Long history of clinical use	Price erosion from generics
Established prescribing habits	Consumer preference shifting to new agents
Cost-effectiveness in developing countries	Regulatory scrutiny over side effects

Final Overview

Paroxetine hydrochloride remains a mature product with limited growth prospects in the traditional antidepressant market. The core revenue streams are driven by generic sales, with heavily compressed margins. Strategic focus on niche formulations, geographic diversification, and partnerships may sustain higher revenue levels.

---

Key Takeaways

• The global antidepressant market was valued at USD 14.9 billion in 2022, with paroxetine representing a significant segment.
• Patent expiries in 2001 led to market saturation by generics, causing revenue declines for original manufacturers.
• Current revenues from paroxetine are estimated at USD 200-300 million annually, primarily from generic formulations.
• Competition is fierce, with bioequivalent generics dominating sales and price competition.
• Opportunities exist in niche formulations and emerging markets, but risks include market saturation and the rise of newer antidepressants.

---

FAQs

Q1: What is the main factor limiting the revenue potential for paroxetine hydrochloride?

A1: Entry of multiple generic manufacturers after patent expiration caused significant price reductions, compressing profit margins.

Q2: How does patent status influence the availability of paroxetine?

A2: Patents expired in 2001, enabling widespread generic entry and elimination of exclusivity rights for brand-name versions.

Q3: Are there any recent regulatory restrictions impacting paroxetine sales?

A3: No major restrictions exist; however, safety alerts related to withdrawal or side effects influence prescriber preferences.

Q4: What are the key growth areas for paroxetine in the future?

A4: Opportunities include specialized formulations, geographic expansion into emerging markets, and combination therapies.

Q5: How does competition from newer antidepressants affect paroxetine’s market?

A5: Newer agents may attract patients seeking fewer side effects, but cost considerations sustain paroxetine’s relevance in budget-conscious settings.

---

References

1. IBISWorld. (2023). Market Research Report: Global Antidepressant Drugs Industry.
2. U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
3. European Medicines Agency. (2023). Marketed Medicinal Products: Paroxetine Publications.